Journal of Personalized Medicine · 2021 · 29 citations · 33 references
MedicineOncologyRadiation OncologyChemotherapyMedical OncologyNeuro-oncologyCombination Cancer TherapyCombination ChemotherapyDose SchedulingGlioma RadiotherapyRadiation TherapyTherapy Response AssessmentCohort ConstructionGlioma ChemotherapyPatient-specific ModelsRadiation Therapy CombinationsRadiation Therapy ResponseTemozolomide TherapyTreatment Cycle SchedulingVirtual Patients
Low-grade gliomas (LGGs) are brain tumors characterized by their slow growth and infiltrative nature. Treatment options for these tumors are surgery, radiation therapy and chemotherapy. The optimal use of radiation therapy and chemotherapy is still under study. In this paper, we construct a mathematical model of LGG response to combinations of chemotherapy, specifically to the alkylating agent temozolomide and radiation therapy. Patient-specific parameters were obtained from longitudinal imaging data of the response of real LGG patients. Computer simulations showed that concurrent cycles of radiation therapy and temozolomide could provide the best therapeutic efficacy in-silico for the patients included in the study. The patient cohort was extended computationally to a set of 3000 virtual patients. This virtual cohort was subject to an in-silico trial in which matching the doses of radiotherapy to those of temozolomide in the first five days of each cycle improved overall survival over concomitant radio-chemotherapy according to RTOG 0424. Thus, the proposed treatment schedule could be investigated in a clinical setting to improve combination treatments in LGGs with substantial survival benefits.
33
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Brigitta G. Baumert, Monika E. Hegi, Martin J. van den Bent et al. · The Lancet Oncology · 2016 · 498 citations · Full text
Medicine, Oncology, Pharmacology +16